MedTrace Logo

Aripiprazole in Children With Autism: A Pilot Study

NCT00208533 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-07-30

No results posted yet for this study

Summary

This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism.

Children who qualify for the study will be treated with aripiprazole for 6 weeks.

Treatment is provided at no cost.

Conditions

Interventions

DRUG

Aripiprazole

Aripiprazole 5 mg to 30mg, individually titrated

Sponsors & Collaborators

  • Drexel University College of Medicine

    lead OTHER

Principal Investigators

  • Richard P Malone, MD · Drexel University College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2011-11-16
Completion
2011-11-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208533 on ClinicalTrials.gov